Should weight loss be the first-line treatment for obstructive sleep apnoea? A pro-con debate.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert pro-con debate summary with no primary data synthesis.
PubMed 42128481 · doi:10.1183/16000617.0255-2025
What was done
This paper summarizes a pro-con debate conducted at the 8th Sleep and Breathing Conference (April 2025) evaluating whether weight loss, specifically incorporating glucagon-like peptide-1 (GLP-1) receptor agonists, should be established as first-line therapy for obstructive sleep apnoea (OSA). It is a narrative review with no primary empirical data collection or systematic meta-analysis.
What was found
The abstract reports no quantitative data, statistics, or effect estimates. It outlines arguments in favor of weight loss (the high proportion of OSA attributable to obesity, the potency of modern pharmacological weight-loss agents, and broader cardiometabolic risk reduction) versus arguments against (a subset of OSA patients are not obese, weight loss does not reliably produce complete OSA resolution, and there are substantial evidence gaps including an absence of direct trials comparing weight loss to continuous positive airway pressure [CPAP] on patient-centered outcomes and long-term health benefits).
Why it matters
As potent obesity pharmacotherapies enter clinical practice, sleep medicine is re-evaluating whether treating the underlying metabolic driver should precede or accompany mechanical airway stenting with CPAP.
Limits
The paper is an expert opinion and narrative debate summary rather than a clinical trial or systematic review. It provides no primary patient data or quantitative syntheses, and it highlights major existing evidence gaps in the broader literature, particularly the lack of head-to-head randomized trials against CPAP.
Cited by
- context Weight loss is typically a first-line treatment for reducing sleep apnea in individuals with excess body weight.